TSE:MFC

Manulife Financial (MFC.TO)

54.00
+0.50 (0.93%)
as of Jun 5, 2026, 8:00:00 pm Market Open.
1636 watching
0
Investor Insights
star iconJun 5, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Manulife Financial (MFC) is viewed positively by several analysts, who note its solid growth in Asia and the wealth management sector. The company is seen as a stable and reliable option, with a decent dividend yield that appeals to income-focused investors. Analysts acknowledge that while MFC has experienced some recent challenges, especially in its U.S. operations and corrections after strong performances, it maintains a healthy growth outlook. Concerns about the overall market and macroeconomic factors have led to suggestions of caution, but many believe MFC's valuation is still attractive relative to its peers, particularly the banks. In the long term, it remains a compelling investment opportunity with the potential for growth, other factors such as credit risk being minimal.

consensus icon
Consensus
Positive
valuation icon
Valuation
Fair Value
review icon
Similar
SLF
BUY
Likes this company and the fee revenue they are generating. Probably a higher growth rate than with the banks.
BUY
Manulife and Sun Life have the capacity to increase their dividends more than the banks, which would be a good alternative to the banks.
DON'T BUY
The integration with John Hancock is going quite well. Too expensive. Would prefer 15/20% cheaper. Feels the street is too optimistic about their future profitability.
TOP PICK
Management has done a remarkable job in growing the company.Savings from the John Hancock takeover is going to be $325 million rather than $255 million. Could take over a bank down the road.
BUY
Likes both Sun Life and Manufacturers Life. Both have more room to increase their dividend payout ratio than the Cdn banks.
BUY
Has pulled back a little along with Cdn financials probably due to higher interest rate concerns. Not a bad entry point. Expects 10% upside including dividends. Very solid company.
BUY ON WEAKNESS
A very strong company. Can't see anything in the Eliot Spitzer investigation that will materially impact the company. Has a large US component, so some currency risk. Low $50's is a good entry point.
BUY ON WEAKNESS
Has been caught in a bit of a downdraft because of the bank reports. Asian operations are starting to fire. Wait until the banking reporting season is over and buy on dips.
BUY
Their #1 in the financial sector. Cash flow yield is 16%. Has a good growth potential with their John Hancock acquisition and their Asian activity. Well run.
WATCH
Currently evaluating. John Hancock acquisition was good. Latest quarterly earnings were disappointing. Expensive relative to other insurance companies but has a better growth profile.
BUY
Prefers Manulife over Sun Life as it has a little bit better growth rate. Trading close to its highs. Good international growth.
BUY
Still in an uptrend. The life companies have one more leg in them. Use a stop/loss of $50/52 in case of a reversal.
BUY
Sees tough sledding for banks growth, so prefers life companies. Likes their Asian exposure where sales are growing at a very heavy rate.
TOP PICK
Has pulled back affected by both the Marsh/McLennan scandal in the US and their recent numbers which were slightly disappointing. A high degree of safety.
TOP PICK
Integration of John Hancock has gone very well. Not affected by the US commission scandal. A global company.
Showing 1,966 to 1,980 of 2,279 entries